Navigation Links
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
Date:3/3/2008

-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contact:

For Indevus:

Michael W. Rogers

Executive Vice President and CFO

(781) 861-8444

Brooke D. Wagner

Vice President, Corporate Communications

(781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
4. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... China (PRWEB) April 28, 2015 Georgia ... major municipalities in China that will partner with the ... reduce smoking in a nation that produces more tobacco ... world. , The project, China Tobacco Control Partnership-Tobacco Free ... leaders have shown willingness to support tobacco control efforts ...
(Date:4/28/2015)... Tools4ever, the market leader in identity ... they have been chosen by IT Central Station ... Access Management vendors. IT Central Station compiled over ... Management tools by real users in 2014 and ... trends to come up with the top ten ...
(Date:4/28/2015)... A new survey from National Stroke Association ... of Americans fear brain damage the most. The results, ... shed light on the need for greater awareness of the ... By controlling modifiable risk factors, 80 percent of strokes ... brain attack ” that occurs when blood flow to the ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 A ... Journal of Molecular Imaging and Biology showed initial ... 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor. The ... University in Baltimore, MD by study co-author, Martin ... human evaluation of [18F]DCFPyL demonstrated a number of ...
(Date:4/28/2015)... 2015 Colorado spine surgeon Donald Corenman, ... his popular spine education website NECKANDBACK.COM and ... eMedical Media. This website has been redesigned to help ... the spine, causes of neck and back pain, and ... website and personally answers questions in the neck and ...
Breaking Medicine News(10 mins):Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Tools4ever Chosen as Part of “Top Identity and Access Management Tools - 2015 Edition” 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3
... ... solutions for the 90 million literacy challenged Americans, including special social media workshop ... La Habra, Calif. ... organization and a national leader in health literacy education and services, will host its ...
... ... client return on investment. , ... (PRWEB) February 2, 2010 -- The current poor economic conditions have driven ... area of focus as companies look for more affordable and efficient ways to reach ...
... ... the American College of Radiology (ACR) , ... Berkeley Heights (Vocus) February 2, 2010 -- Summit Medical Group’s ... for the period of January 2010 through January 2013. Accreditation by the ACR is ...
... , FREEHOLD, N.J. , Feb. 2 Speedus Corp. ... it received notice from Nasdaq, in the form of a staff ... of the extension granted to the Company on December 11, 2009 ... 5550(b) (the "Rule"), which requires the Company to maintain either (1) a ...
... better, study found , TUESDAY, Feb. 2 (HealthDay News) -- ... will be able to kick the habit and reduces the ... found. , The study included 568 adults who smoked 10 ... year. The smokers who used nicotine patches for the entire ...
... INDIANAPOLIS , Feb. 2 WellPoint, Inc. (NYSE: ... to present at the UBS 20th Annual Global Healthcare Services Conference ... Standard Time .   , All interested parties are invited to ... www.wellpoint.com and selecting the "Investor Info" link. Following the ...
Cached Medicine News:Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 2Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 3Health News:Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times 2Health News:Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times 3Health News:Nuclear Medicine at Summit Medical Group Earns ACR Re-Accreditation 2Health News:Speedus Receives and Appeals Nasdaq Notice 2Health News:Using Nicotine Patch Longer Boosts Efforts to Quit 2Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:WellPoint Announces Appearance at Upcoming Conference 3
(Date:4/28/2015)...  Olympus, a precision technology leader in designing and ... other core businesses, announced today the opening of its ... MN. The new medical device research & ... company for continued long-term growth in the surgical sector. ... on April 27 and was attended by Mark ...
(Date:4/28/2015)... 28, 2015  Securities lawyers at Dunnam & ... ANGO ). Concerned ANGO investors who purchased between ... to contact securities attorney Hamilton Lindley by clicking ... 9, 2015, a quarterly loss of $4.3 million and ... year to a range of $356 million to $360 ...
(Date:4/28/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( http://www.oramed.com ... I am very excited to announce that we are on ... for oral insulin (ORMD-0801) and the treatment of type 2 ... coming weeks. This clinical trial will be our largest and most ... the company, literally putting us in a different place. ...
Breaking Medicine Technology:Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
... continue the outstanding worldwide ... microscopes in medical and ... UIS infinity-corrected optics. The ... performance and even greater ...
... Coolscope operates with a simple click ... display. Direct the mouse cursor to ... image of the slide and the ... intuitive Graphic User Interface (GUI) enables ...
... Eclipse TS100 is an innovative ... This high quality tool complements ... and increased stability - Nikon ... vibration resistant design that greatly ...
Carbide drill bits, cutters, side cutting. Available in various sizes....
Medicine Products: